Get the Stockscreener App
1.42
5.19%
0.07
After Hours:
1.42
Pds Biotechnology Corporation stock is traded at $1.42, with a volume of 524.75K.
It is up +5.19% in the last 24 hours and up +36.54% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.35
Open:
$1.37
24h Volume:
524.75K
Relative Volume:
0.87
Market Cap:
$64.85M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.2137
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+18.33%
1M Performance:
+36.54%
6M Performance:
-29.35%
1Y Performance:
-59.77%
1-Day Range:
$1.36
$1.45
1-Week Range:
$1.21
$1.45
52-Week Range:
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.42 | 54.81M | 0 | -40.56M | -35.28M | -1.17 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - Insider Monkey
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PDSB Advances with Phase 3 Trial for Versamune HPV Therapy | PDS - GuruFocus
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Trial and Announces Abstracts Selected for ASCO 2025 - Nasdaq
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update - TradingView
PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday - Defense World
Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
PDS Biotechnology Unveils Promising Flu Vaccine Data - TipRanks
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results - TradingView
Marshall Wace LLP Has $64,000 Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Renaissance Technologies LLC Acquires 76,800 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
THE CANADIAN INTERNATIONAL TRADE TRIBUNAL TERMINATES ITS PRELIMINARY INJURY INQUIRY IN RESPECT OF TIDEWATER RENEWABLES LTD.'S COUNTERVAILING (ANTI-SUBSIDY) AND ANTI-DUMPING DUTY COMPLAINT RELATING TO I - The Globe and Mail
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
B. Riley Adjusts Price Target on PDS Biotechnology to $5 From $7, Maintains Buy Rating - marketscreener.com
B. Riley Expects Stronger Earnings for PDS Biotechnology - Defense World
PDS Biotechnology Director Sir Richard Sykes Retires - TipRanks
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune® HPV Immunotherapy - Nasdaq
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
3 Reasons to Avoid GAP and 1 Stock to Buy Instead - The Globe and Mail
PDSB stock touches 52-week low at $1.12 amid market challenges - Investing.com
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):